For Abbott Laboratories [ABT], Analyst sees a rise to $146. What next?


Abbott Laboratories [NYSE: ABT] closed the trading session at $135.70 on 01/11/22. The day’s price range saw the stock hit a low of $134.04, while the highest price level was $135.97. The company report on January 11, 2022 that Abbott Named One of America’s Most JUST Companies by JUST Capital and CNBC for Sustainable Business Leadership.

The JUST 100 ranking recognizes socially just companies responding to the needs of employees, customers, communities and all stakeholders.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


The stocks have a year to date performance of -3.58 percent and weekly performance of -0.05 percent. The stock has been moved at 15.81 percent over the last six months. The stock has performed 0.99 percent around the most recent 30 days and changed 15.67 percent over the most recent 3-months.

If compared to the average trading volume of 5.33M shares, ABT reached to a volume of 5684888 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here’s what leading stock market gurus have to say about Abbott Laboratories [ABT]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ABT shares is $144.68 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ABT stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

RBC Capital Mkts have made an estimate for Abbott Laboratories shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on December 10, 2021. The new note on the price target was released on October 27, 2021, representing the official price target for Abbott Laboratories stock.

The Average True Range (ATR) for Abbott Laboratories is set at 2.47, with the Price to Sales ratio for ABT stock in the period of the last 12 months amounting to 5.65. The Price to Book ratio for the last quarter was 6.99, with the Price to Cash per share for the same quarter was set at 5.50. Price to Free Cash Flow for ABT in the course of the last twelve months was 38.16 with Quick ratio for the last quarter at 1.40.

ABT stock trade performance evaluation

Abbott Laboratories [ABT] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -0.05. With this latest performance, ABT shares gained by 0.99% in over the last four-week period, additionally plugging by 15.81% over the last 6 months – not to mention a rise of 24.68% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ABT stock in for the last two-week period is set at 51.14, with the RSI for the last a single of trading hit 45.30, and the three-weeks RSI is set at 54.04 for Abbott Laboratories [ABT]. The present Moving Average for the last 50 days of trading for this stock 132.11, while it was recorded at 135.36 for the last single week of trading, and 122.95 for the last 200 days.

Abbott Laboratories [ABT]: An insightful look at the core fundamentals

Operating Margin for any stock indicates how profitable investing would be, and Abbott Laboratories [ABT] shares currently have an operating margin of +15.29 and a Gross Margin at +50.21. Abbott Laboratories’s Net Margin is presently recorded at +12.86.

Return on Total Capital for ABT is now 10.24, given the latest momentum, and Return on Invested Capital for the company is 8.83. Return on Equity for this stock inclined to 13.93, with Return on Assets sitting at 6.34. When it comes to the capital structure of this company, Abbott Laboratories [ABT] has a Total Debt to Total Equity ratio set at 60.67. Additionally, ABT Total Debt to Total Capital is recorded at 37.76, with Total Debt to Total Assets ending up at 27.42. Long-Term Debt to Equity for the company is recorded at 59.26, with the Long-Term Debt to Total Capital now at 36.89.

Reflecting on the efficiency of the workforce at the company, Abbott Laboratories [ABT] managed to generate an average of $40,817 per employee. Receivables Turnover for the company is 5.85 with a Total Asset Turnover recorded at a value of 0.49.Abbott Laboratories’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.40 and a Current Ratio set at 1.80.

Earnings per share (EPS) analysis for Abbott Laboratories [ABT] stock

The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ABT. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Abbott Laboratories go to 13.12%.

>> 7 Top Picks for the Post-Pandemic Economy <<

Abbott Laboratories [ABT]: Insider Ownership positions

There are presently around $175,141 million, or 75.50% of ABT stock, in the hands of institutional investors. The top three institutional holders of ABT stocks are: VANGUARD GROUP INC with ownership of 148,779,946, which is approximately 0.633% of the company’s market cap and around 0.20% of the total institutional ownership; BLACKROCK INC., holding 134,318,636 shares of the stock with an approximate value of $18.23 billion in ABT stocks shares; and CAPITAL RESEARCH GLOBAL INVESTORS, currently with $11.46 billion in ABT stock with ownership of nearly -1.594% of the company’s market capitalization.

Positions in Abbott Laboratories stocks held by institutional investors increased at the end of January and at the time of the January reporting period, where 1,127 institutional holders increased their position in Abbott Laboratories [NYSE:ABT] by around 40,225,938 shares. Additionally, 1,063 investors decreased positions by around 40,715,643 shares, while 410 investors held positions by with 1,209,708,809 shares. The mentioned changes placed institutional holdings at 1,290,650,390 shares, according to the latest SEC report filing. ABT stock had 132 new institutional investments in for a total of 6,026,447 shares, while 83 institutional investors sold positions of 2,112,719 shares during the same period.